BioGaia (BIOG B) Stock Overview
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BIOG B Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 118.80 |
| 52 Week High | SEK 136.30 |
| 52 Week Low | SEK 93.20 |
| Beta | 0.30 |
| 1 Month Change | -7.69% |
| 3 Month Change | 1.45% |
| 1 Year Change | 13.68% |
| 3 Year Change | 2.41% |
| 5 Year Change | 21.10% |
| Change since IPO | 1,403.80% |
Recent News & Updates
Narrative Update • Jun 23
BIOG B: Dividend Strength And Skincare Expansion Will Support Future Rerating
Analysts have trimmed their price target on BioGaia to SEK165. This reflects a slightly higher discount rate and modestly adjusted long term assumptions following more cautious recent research.Analysis Article • Jun 21
BioGaia (OM:BIOG B) Stock Could Be 28.4% Undervalued After Skincare Expansion
BioGaia (OM:BIOG B) has drawn fresh investor attention after expanding its BioGaia Skincare portfolio with two microbiome-focused products for babies and children, along with updated packaging and recent launches in China and the US. See our latest analysis for BioGaia. The new skincare launches arrive after a mixed period for BioGaia’s stock, with the share price at SEK118.2, a 30 day share price return down 9.7% but a year to date share price return of 12.57% and a 1 year total shareholder...Narrative Update • Jun 08
BIOG B: Dividend Support And LongevityGuard Stability Will Underpin Future Re Rating
Analysts have trimmed their outlook on BioGaia, reducing the SEK price target by SEK 165. They cite a more cautious stance following recent research commentary, including a downgrade from SEB Equities.Narrative Update • May 24
BIOG B: Margin Resilience And LongevityGuard Technology Will Support Future Re Rating
The updated analyst price target for BioGaia has moved from SEK 140 to SEK 165, with analysts pointing to adjusted assumptions around revenue growth, profit margins, and future P/E expectations, even as some recent research has turned more cautious on the stock. Analyst Commentary Analyst views on BioGaia are mixed, with some focusing on the higher SEK 165 price target and others turning more cautious after recent research updates.Recent updates
Narrative Update • Jun 23
BIOG B: Dividend Strength And Skincare Expansion Will Support Future Rerating
Analysts have trimmed their price target on BioGaia to SEK165. This reflects a slightly higher discount rate and modestly adjusted long term assumptions following more cautious recent research.Analysis Article • Jun 21
BioGaia (OM:BIOG B) Stock Could Be 28.4% Undervalued After Skincare Expansion
BioGaia (OM:BIOG B) has drawn fresh investor attention after expanding its BioGaia Skincare portfolio with two microbiome-focused products for babies and children, along with updated packaging and recent launches in China and the US. See our latest analysis for BioGaia. The new skincare launches arrive after a mixed period for BioGaia’s stock, with the share price at SEK118.2, a 30 day share price return down 9.7% but a year to date share price return of 12.57% and a 1 year total shareholder...Narrative Update • Jun 08
BIOG B: Dividend Support And LongevityGuard Stability Will Underpin Future Re Rating
Analysts have trimmed their outlook on BioGaia, reducing the SEK price target by SEK 165. They cite a more cautious stance following recent research commentary, including a downgrade from SEB Equities.Narrative Update • May 24
BIOG B: Margin Resilience And LongevityGuard Technology Will Support Future Re Rating
The updated analyst price target for BioGaia has moved from SEK 140 to SEK 165, with analysts pointing to adjusted assumptions around revenue growth, profit margins, and future P/E expectations, even as some recent research has turned more cautious on the stock. Analyst Commentary Analyst views on BioGaia are mixed, with some focusing on the higher SEK 165 price target and others turning more cautious after recent research updates.Narrative Update • May 05
BIOG B: Extra Dividend And Margin Resilience Will Support Future Re Rating
Analysts now maintain a SEK 140.0 price target for BioGaia, using a slightly lower discount rate and similar long term growth and margin assumptions. At the same time, some recent research has turned more cautious on the stock’s outlook.Narrative Update • Apr 19
BIOG B: Extra Dividend And Margin Resilience Will Support Future Multiple Re Rating
Analysts held their fair value estimate for BioGaia steady at SEK 140 while making slight adjustments to the discount rate, profit margin, and future P/E assumptions. This reflects a more cautious stance following recent downgrades in Street research.Narrative Update • Apr 05
BIOG B: Downgrade And Extra Dividend Will Set Up Future Multiple Re Rating
Analysts have trimmed their stance on BioGaia with a lower SEK price target, reflecting more cautious views on the shares following a downgrade from SEB Equities and only slight adjustments to assumptions such as the discount rate and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the trimmed price target and modest changes to the discount rate and future P/E as leaving room for upside if execution on growth initiatives tracks current expectations.Narrative Update • Mar 21
BIOG B: Extra Dividend And Stable Margins Will Support Higher Earnings Multiple
Analysts have maintained their price target for BioGaia at SEK 140, citing essentially unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Renewed distribution agreement with Ewopharma covering more than 15 European countries, expanding access to BioGaia's probiotic portfolio across Central Eastern Europe and Switzerland (Key Developments).Narrative Update • Mar 06
BIOG B: Extra Dividend And Solid Margins Will Support Higher Earnings Multiple
Analysts have maintained their SEK 140.0 fair value estimate for BioGaia, citing only minor adjustments to the discount rate and to long-term assumptions on revenue growth, profit margins and future P/E as the basis for keeping their price target unchanged. What's in the News BioGaia renewed and extended its distribution agreement with Ewopharma, which will now distribute a broad range of BioGaia products in more than 15 European countries, with a focus on Central Eastern Europe and Switzerland (Key Developments).Narrative Update • Feb 20
BIOG B: Dividend Reset And Solid Margins Will Support Higher Future Earnings Multiple
Analysts have kept their SEK 140.0 price target for BioGaia broadly unchanged, citing slightly higher assumed discount rates and a modestly lower profit margin outlook. These factors are largely offset by stable long term growth and P/E expectations.Narrative Update • Feb 05
BIOG B: Serotonin Producing Gut Bacteria Will Support Higher Future Earnings Multiple
Analysts have maintained their fair value estimate for BioGaia at SEK 140.0, with only slight technical adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a largely unchanged price target narrative. Valuation Changes Fair Value: Kept steady at SEK 140.0, indicating no change in the headline valuation level.Narrative Update • Jan 22
BIOG B: Serotonin Producing Gut Bacteria Will Support Higher Future Earnings Multiple
Narrative Update on BioGaia The analyst price target for BioGaia is unchanged at €140. Analysts consider the slightly higher discount rate and modestly adjusted future P/E assumption to be offsetting factors that leave their valuation view effectively intact.Narrative Update • Jan 07
BIOG B: Serotonin Link In Gut Microbiota Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for BioGaia from SEK 130 to SEK 140, citing updated assumptions for discount rates, revenue growth, profitability and future P/E that they see as better aligned with the company’s current outlook. What's in the News Researchers linked to BioGaia reported that specific gut bacteria can produce serotonin, a key bioactive substance in the microbiota gut brain axis, with findings published in Cell Reports (Key Developments).Narrative Update • Aug 20
Expanding North American Demand Will Unlock New Health Trends
The consensus price target for BioGaia has been revised down to SEK130.00, primarily reflecting a decline in the company’s expected future P/E ratio. What's in the News BioGaia launched a subsidiary, BioGaia New Sciences AB, to develop microbiome-friendly products beyond gut, immune, and oral health, focusing first on skin health.
New Narrative • Feb 22
Launch Of Gastrus PURE ACTION And Direct Operations Will Strengthen Future Prospects
Direct market investments and internalizing operations in key regions enhance revenue potential by reducing reliance on distributors and capturing full retail margins.Analysis Article • Oct 29
BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with BioGaia AB (publ)'s ( STO:BIOG B ) lackluster earnings report last week. We did...Analysis Article • Apr 25
BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
BioGaia AB (publ)'s ( STO:BIOG B ) dividend will be increasing from last year's payment of the same period to SEK6.90...Analysis Article • Apr 09
BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
The board of BioGaia AB (publ) ( STO:BIOG B ) has announced that it will be paying its dividend of SEK6.90 on the 15th...Analysis Article • Mar 26
BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
BioGaia AB (publ)'s ( STO:BIOG B ) dividend will be increasing from last year's payment of the same period to SEK6.90...Analysis Article • Mar 09
BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90
BioGaia AB (publ) ( STO:BIOG B ) will increase its dividend from last year's comparable payment on the 15th of May to...Analysis Article • Feb 24
BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
BioGaia AB (publ) ( STO:BIOG B ) will increase its dividend from last year's comparable payment on the 15th of May to...Analysis Article • Feb 10
BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
The board of BioGaia AB (publ) ( STO:BIOG B ) has announced that it will be paying its dividend of SEK6.90 on the 15th...Analysis Article • Nov 27
Here's Why We Think BioGaia (STO:BIOG B) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Sep 13
Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Key Insights The projected fair value for BioGaia is kr95.22 based on 2 Stage Free Cash Flow to Equity BioGaia's...Analysis Article • Jun 02
Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Apr 27
A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioGaia fair value estimate is kr91.40 With kr97.30 share...Shareholder Returns
| BIOG B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.5% | 4.9% | -0.06% |
| 1Y | 13.7% | 32.4% | 13.5% |
Return vs Industry: BIOG B underperformed the Swedish Biotechs industry which returned 32.4% over the past year.
Return vs Market: BIOG B matched the Swedish Market which returned 13.5% over the past year.
Price Volatility
| BIOG B volatility | |
|---|---|
| BIOG B Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BIOG B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOG B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 243 | Theresa Agnew | www.biogaiagroup.com |
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.
BioGaia AB (publ) Fundamentals Summary
| BIOG B fundamental statistics | |
|---|---|
| Market cap | SEK 12.11b |
| Earnings (TTM) | SEK 331.98m |
| Revenue (TTM) | SEK 1.54b |
36.2x
P/E Ratio7.8x
P/S RatioIs BIOG B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOG B income statement (TTM) | |
|---|---|
| Revenue | SEK 1.54b |
| Cost of Revenue | SEK 417.46m |
| Gross Profit | SEK 1.13b |
| Other Expenses | SEK 795.02m |
| Earnings | SEK 331.98m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 17, 2026
| Earnings per share (EPS) | 3.28 |
| Gross Margin | 72.97% |
| Net Profit Margin | 21.49% |
| Debt/Equity Ratio | 0% |
How did BIOG B perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 17:52 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioGaia AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Uhde | ABG Sundal Collier Sponsored |
| Mattias Häggblom | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |